Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1446881 | 0.83 | S1PR2 (0.56) | S1PR2OTUD7BSMN1; SMN2USP2ALDH1A1 | |
| SCHEMBL1446649 | 0.79 | LIMK2 (0.57) | LMNAKHK | |
| SCHEMBL4290419 | 0.79 | S1PR2 (0.52) | S1PR2OTUD7BSMN1; SMN2USP2CYP2D6 | |
| SCHEMBL346082 | 0.77 | MMP3 (0.40) | F10FAAHMMP3MMP10 | |
| SCHEMBL14964355 | 0.77 | S1PR2 (0.50) | S1PR2OTUD7BSMN1; SMN2USP2CYP2D6 | |
| SCHEMBL14384856 | 0.76 | MTNR1A (0.64) | SMN1; SMN2CDK8ALDH1A1LMNAMAPT | |
| SCHEMBL20224882 | 0.75 | CYP1A2 (0.52) | SMN1; SMN2CYP2D6ALDH1A1CYP2C19LMNA | |
| SCHEMBL4290392 | 0.75 | LIMK2 (0.62) | — | |
| SCHEMBL4302014 | 0.75 | LIMK2 (0.59) | — | |
| SCHEMBL1446943 | 0.74 | LIMK2 (0.53) | SMN1; SMN2USP2CYP2D6ALOX15LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297153-B1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2015-05-27 | — | — | EP | disclosed |
| EP-2674433-A1 | LIMK2 inhibitors, compositions comprising them and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8450332-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-12-27 | — | — | US | disclosed |
| US-8193202-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2297153-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009131940-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | S1PR2 2804/4885F10 4228/4885OTUD7B 3051/4885 |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | S1PR2 2804/4885F10 4228/4885OTUD7B 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.